Influenza A viruses cause a spectrum of responses, from mild cold-like symptoms to severe respiratory illness and death. Viral strains and intrinsic host factors, such as age, can influence the severity of the disease. Glycosylation plays a critical role in influenza pathogenesis, however the molecular drivers of influenza outcomes remain unknown. In this work, we characterized the glycomic response to the H1N1 2009 pandemic influenza A virus in age-dependent severity. Using a ferret model and a lectin microarray technology we have developed, we compared responses in newly weaned and aged animals, a model for young children and the elderly, respectively. Glycomic analysis revealed changes in glycosylation over the course of the infection, that were associated with severity in an age-dependent manner. These responses may help explain the differential susceptibility to influenza A virus infection of young children and the elderly.

The role and impact of viral infections remain a subject of interest, yet comparative data on influenza A/B, RSV, and SARS-CoV-2 in both hospitalized and non-hospitalized patients are limited. In this observational study, we analyzed data from adult patients with respiratory infections who underwent rapid testing for Influenza A/B, RSV, SARS-CoV-2, and Adenovirus between October 2023 and March 2024. Symptoms at emergency department presentation, laboratory results, risk factors, clinical course, and outcomes were assessed. Among 1,402 patients with respiratory infections, Influenza A was the most prevalent virus and the leading cause of hospitalizations, with the longest stay (mean: 9.86 days). SARS-CoV-2 was the second most common, primarily affecting older patients (mean age: 79 years), associated with the highest in-hospital mortality. RSV ranked third in prevalence, had the highest hospitalization rate among those infected, and was characterized by bronchospasm, with 25% of hospitalized patients requiring high-flow nasal cannula (HFNC). Influenza B primarily affected younger individuals and had a negligible hospitalization rate. SARS-CoV-2 patients sought care the fastest, while RSV patients had the most prolonged symptom duration before seeking medical attention. Despite differences in care-seeking timing, most Flu-A, Flu-B, and SARS-CoV-2 patients recovered within 2-5 days, with no significant difference observed. Vaccine effectiveness against Influenza A was 49.5%. This estimate should be interpreted with caution due to potential confounding by age and comorbidities. These findings offer comparative insights into the clinical burden of respiratory viruses during the 2023-2024 season, reflecting patterns in the post-pandemic era.

the disease is severe, the term "flu-like" or "influenza-like illness" can be used instead. Well over 200 virus strains are implicated in causing the The common cold, or simply a cold, is a viral infectious disease of the upper respiratory tract that primarily affects the respiratory mucosa of the nose, throat, sinuses, and larynx. Signs and symptoms may appear in as little as two days after exposure to the virus. These may include coughing, sore throat, runny nose, sneezing, headache, fatigue, and fever. People usually recover in seven to ten The common cold, or simply a cold, is a viral infectious disease of the upper respiratory tract that primarily affects the respiratory mucosa of the nose, throat, sinuses, and larynx. Signs and symptoms may appear in as little as two days after exposure to the virus. These may include coughing, sore throat, runny nose, sneezing, headache, fatigue, and fever. People usually recover in seven to ten days, but some symptoms may last up to three weeks. Occasionally, those with other health problems may develop pneumonia. When general symptoms are systemic and the disease is severe, the term "flu-like" or "influenza-like illness" can be used instead. Well over 200 virus strains are implicated in causing the common cold, with enteroviruses (especially rhinoviruses), coronaviruses, and adenoviruses being the most common. They spread through the air or indirectly through contact with objects in the environment, followed by transfer to the mouth or nose. Risk factors include going to child care facilities, not sleeping well, and psychological stress. The symptoms are mostly due to the body's immune response to the infection rather than to tissue destruction by the viruses themselves. The symptoms of influenza are similar to those of a cold, although usually more severe and less likely to include a runny nose. There is no vaccine for the common cold. This is due to the rapid mutation and wide variation of viruses that cause the common cold. The primary methods of prevention are hand washing; not touching the eyes, nose or mouth with unwashed hands; and staying away from sick people. People are considered contagious as long as the symptoms are still present. Some evidence supports the use of face masks. There is also no cure, but the symptoms can be treated. Zinc may reduce the duration and severity of symptoms if started shortly after the onset of symptoms. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may help with pain. Antibiotics, however, should not be used, as all colds are caused by viruses rather than bacteria. There is no good evidence that cough medicines prevent or reduce the duration of a cold. The common cold is the most frequent infectious…

Causative agents Avian influenza is caused by influenza A viruses. Influenza viruses are grouped into … tract infection that may mimic a cold is called influenza, or the flu. Flu is usually distinguishable … latter part of 2005. 192 influenza A viruses can cause pan- demics. Influenza A viruses have 16 H sub-

types of influenza virus, influenza A and influenza B, cause “flu” in humans. Influenza A is … age, or a medical condition that directly affects the brain, such as a stroke or a tumor … commercial product, whether an exercise system, a partic¬ ular type of equipment, or a health club